DOT_newsroom

2020 Interviews

Coming Soon.

2019 Interviews


BITW NewsroomInterview: Therapeutic Antibody Affinity Maturation by Cell Surface Display: Closing the Gap

AUGUST 14, 2019 | BIO IT WORLD NEWS

Agnieszka Kielczewska, Senior Scientist, Antibody Discovery, Amgen, Canada
Kielczewska describes her team’s novel affinity maturation approach to help “close” an affinity gap without compromising binding affinity to the human target.


BITW NewsroomInterview: How Paratope Refinement Can Mitigate Antibody Polyspecificity

JULY 3, 2019 | BIO IT WORLD NEWS

Jonny Finlay, PhD, CSO, Ultrahuman, United Kingdom
Finlay discusses the role of polyspecificity in the toxicity and side effects of checkpoint inhibitors, the solvability of the problem, and where bottlenecks occur during the development stage of biotherapeutic R&D


BITW NewsroomInterview: Tackling the Clinical and Preclinical Progress in Targeting Membrane Proteins

JUNE 24, 2019 | BIO IT WORLD NEWS

Catherine Hutchings, PhD, Independent Consultant, United Kingdom
Hutchings describes her work tracking the progress in developing biotherapeutics against GPCR and ion channel targets, the successes and failures of targeting membrane proteins, and what technologies in the R&D space have the potential to be game changers.


Interview: Why inhibit Ketohexokinase (KHK) to treat NASH?

MARCH 6, 2019 | DISCOVERY ON TARGET

Kendra K. Bence, PhD, Senior Director, Metabolism, Internal Medicine Research Unit (IMRU), Pfizer, Inc.
Dr. Bence explains why and how Pfizer scientists developed an inhibitor against ketohexokinase as a drug candidate for non-alcoholic steatohepatitis (NASH), a form of liver fibrosis.


DomainTherapeuticsDWN NewsroomWhitepaper: Leveraging Years of Data on GPCRs for Transformative Drug Discovery

2019 | DIAGNOSTICS WORLD NEWS

GPCRs, which play a role in most biological processes, remain one of the most vibrant fields for drug discovery. Years of data are increasingly being leveraged to overcome the complexity of GPCR biology and pharmacology and accelerate GPCR drug discovery. It is now possible to hope to rationally design drugs with optimal effects, thanks to a better understanding of the concept of functional selectivity.